ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells

Castration-resistant prostate cancer (CRPC) expresses high levels of the anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1, resulting in resistance to apoptosis and association with poor prognosis. Docetaxel, an antimitotic drug that is the first-line treatment strategy for CRPC, is known to provide a...

Full description

Bibliographic Details

Published in:	PeerJ
Main Authors:	Ricardo Parrondo, Alicia de las Pozas, Teresita Reiner, Carlos Perez-Stable
Format:	Article
Language:	English
Published:	PeerJ Inc. 2013-09-01
Subjects:	Apoptosis Antimitotic ABT-737 Bcl-2 family Cyclin B1/Cdk1
Online Access:	https://peerj.com/articles/144.pdf